Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
Biopesticide AgTech building toward RNAissance with TechAccel cultivation
KC-based TechAccel endeavors to guide startups through “the valley of death” stage that emerges after ideation, but before traction, said Brad Fabbri, noting the firm’s new venture, RNAissance Ag, is expected to disrupt the ag tech industry with environmentally-safe biopesticides. “We try to find products and help develop them to make [farmers’] lives easier and…
Digital Sandbox charges three new startups with its proof-of-concept challenge
An effort to elevate Kansas City’s creative minds, Digital Sandbox KC is digging deeper in its sixth year of acceleration — adding three new startups to its portfolio, the proof-of-concept program announced this week. “Our initial goal was to find 10 early-stage concepts that had high-growth potential and help them secure follow-on funding,” said Jeff Shackelford,…
KCultivator Q&A: Donald Hawkins chews on sage advice, blood sausage, ‘circle of giving’
Editor’s note: KCultivators is a lighthearted profile series to highlight people who are meaningfully enriching Kansas City’s entrepreneurial ecosystem. Founders should rally around Kansas City’s startup ecosystem like fans rallied around the Chiefs, said Donald Hawkins. “If you look at a lot of the companies that have scaled — there’s a huge connection gap between…
‘Hardest deal is always the first one’ — Partnership adapts Motega Health tech for animal use
A new licensing deal with Simini Technologies has unleashed disruptive potential for Lawrence-built Motega Health, the company announced Thursday. “We are very pleased to be partnering with Simini and their team and are excited by the energy and creative thinking they are bringing to the commercial process in veterinary medicine,” said Dr. Blake Hawley, founder…